This week, the F.D.A. commissioner announced a decision requiring stricter warnings on labels for Avandia and Actos, two oral medications for diabetes. After a year long review, the FDA determined that the Avandia"can potentially cause heart attacks or other cardiovascular problems" and Actos, a competitor, carries a risk of heart failure. Today's New York Times reports that {i]n a written...